Table 4.

Baseline Characteristics of 228 Patients (Treated with Peg IFN Plus Ribavirin) and Treatment Response.

Variable	Total		aGenotype 1		bGenotype 3		(P value)
	SVR	No SVR	SVR	No SVR	SVR	No SVR
Age							<0.001
<40	96 (78.0%)	27 (22.0%)	23 (69.7%)	10 (30.3%)	73 (81.1%)	17 (18.9%)	a0.047
≥40	59 (56.2%)	46 (43.8%)	14 (45.2%)	17 (54.8%)	45 (60.8%)	29 (39.2%)	b0.004
Gender							0.089
Male	104 (64.6%)	57 (35.4%)	25 (55.6%)	20 (44.4%)	79 (68.1%)	37 (31.9%)	a0.574
Female	51 (76.1%)	16 (23.9%)	12 (63.2%)	7 (36.8%)	39 (81.3%)	9 (18.8%)	b0.088
BMI							0.314
<23	78 (69.6%)	34 (30.4%)	19 (57.6%)	14 (42.4%)	59 (74.7%)	20 (25.3%)	a0.242
≥23 to <25	29 (67.4%)	14 (32.6%)	6 (85.7%)	1 (14.3%)	23 (63.9%)	13 (36.1%)	b0.471
≥25	48 (65.8%)	25 (34.2%)	12 (50.0%)	12 (50.0%)	36 (73.5%)	13 (26.5%)	0.301
DM	16 (59.3%)	11 (40.7%)	3 (42.9%)	4 (57.1%)	13 (65.0%)	7 (35.0%)	a0.443
Non diabetic	139 (69.2%)	62 (30.8%)	34 (59.6%)	23 (40.4%)	105 (72.9%)	39 (27.1%)	b0.449
Alcohol intake							0.037
≥30 g/d	13 (50.0%)	13 (50.0%)	1 (33.3%)	2 (66.7%)	12 (52.2%)	11 (47.8%)	a0.379
No alcohol intake	142 (70.3%)	60 (29.7%)	36 (59.0%)	25 (41.0%)	106 (75.2%)	35 (24.8%)	b0.023
Fibrosis
F1	80 (76.2%)	25 (23.8%)	24 (64.9%)	13 (35.1%)	56 (82.4%)	12 (17.6%)	0.006
F2	23 (76.7%)	7 (23.3%)	6 (75.0%)	2 (25.0%)	17 (77.3%)	5 (22.7%)	a0.155
F3	21 (65.6%)	11 (34.4%)	3 (33.3%)	6 (66.7%)	18 (78.3%)	5 (21.7%)	b0.004
F4	31 (50.8%)	30 (49.2%)	4 (40.0%)	6 (60.0%)	27 (52.9%)	24 (47.1%)
HCV RNA							0.336
≤600,000 IU/ml	87 (70.7%)	36 (29.3%)	17 (60.7%)	11 (39.3%)	70 (73.7%)	25 (26.3%)	a0.678
>600,000 IU/ml	68 (64.8%)	37 (35.2%)	20 (55.6%)	16 (44.4%)	48 (69.6%)	21 (30.4%)	b0.562
RVR (n = 151)	126 (83.4%)	25 (16.6%)	25/(78.1%)	7 (21.9%)	101 (84.9%)	18 (15.1%)	0.001
NoRVR (n 77)	29 (37.7%)	48 (62.3%)	12 (37.5%)	20 (62.5%)	17 (37.8%)	28 (62.2%)
EVR (n = 192)	153 (79.7%)	39 (20.3%)	37 (77.1%)	11 (22.9%)	115 (78.2%)	32 (21.8%)	0.001
NoEVR (n 36)	(8.3%)	33 (91.7%)	0/(%)	16 (100%)	3 (17.6%)	14 (82.4%)

Bold signifies p< 0.05